FDA Approves Nivolumab for Resected Stage IIB/C Melanoma

The new approval expands the melanoma indication for nivolumab to earlier-stage disease.

Related Keywords

Bristol Myers Squibb ,Drug Administration ,Myers Squibb ,Melanoma ,Malignant Melanoma ,Skin Cancer ,Alignant Skin Neoplasm ,Disease Recurrence ,Sentinel Lymph Node ,Toxicology ,Alabama ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Fatigue ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Grant ,Intravenous Iv ,Intravenous ,Tv ,Lymph Nodes ,Orphan Drugs ,Spain ,Receptors ,Presection ,Pain Management ,Diarrhea ,